Literature DB >> 15591515

Adiponectin and its receptors in non-alcoholic steatohepatitis.

S Kaser1, A Moschen, A Cayon, A Kaser, J Crespo, F Pons-Romero, C F Ebenbichler, J R Patsch, H Tilg.   

Abstract

BACKGROUND: Adiponectin, an adipocyte derived polypeptide, has been shown to alleviate steatosis and inflammation in mice with non-alcoholic fatty liver disease. AIM: In the present study, we wished to define liver expression of adiponectin and its receptors in morbidly obese patients undergoing bariatric surgery. Patients with non-alcoholic steatohepatitis (NASH) or simple steatosis were investigated to test whether dysregulation of this system might be involved in these disorders. PATIENTS AND METHODS: Liver mRNA expression of adiponectin and its recently cloned receptors RI and RII (adipoRI and adipoRII) were analysed by fluorescence based real time polymerase chain reaction in 13 patients with NASH and nine with simple steatosis. Adiponectin and adipoRII protein expression were assessed by immunohistochemistry in a subgroup of patients.
RESULTS: Adiponectin and adipoRII mRNA expression were significantly reduced in liver biopsies of patients with NASH compared with simple steatosis while no difference was found in adipoRI mRNA expression. In NASH, adipoRII mRNA expression was negatively correlated with serum aspartate aminotransferase levels, serum alanine aminotransferase levels, and grade of fibrosis. Liver adiponectin protein expression was mainly found in endothelial cells of portal vessels and liver sinusoids whereas adipoRII expression was seen in hepatocytes only. Adiponectin and adipoRII staining were lower in biopsies of subjects with NASH compared with simple steatosis.
CONCLUSION: Reduced hepatic expression of adiponectin and adipoRII might be of pathophysiological relevance in non-alcoholic fatty liver diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15591515      PMCID: PMC1774357          DOI: 10.1136/gut.2003.037010

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  16 in total

Review 1.  Cytokines in alcoholic and nonalcoholic steatohepatitis.

Authors:  H Tilg; A M Diehl
Journal:  N Engl J Med       Date:  2000-11-16       Impact factor: 91.245

2.  The adipocyte-secreted protein Acrp30 enhances hepatic insulin action.

Authors:  A H Berg; T P Combs; X Du; M Brownlee; P E Scherer
Journal:  Nat Med       Date:  2001-08       Impact factor: 53.440

Review 3.  Resistin and obesity-associated insulin resistance.

Authors:  Claire M Steppan; Mitchell A Lazar
Journal:  Trends Endocrinol Metab       Date:  2002 Jan-Feb       Impact factor: 12.015

4.  Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients.

Authors:  J Crespo; A Cayón; P Fernández-Gil; M Hernández-Guerra; M Mayorga; A Domínguez-Díez; J C Fernández-Escalante; F Pons-Romero
Journal:  Hepatology       Date:  2001-12       Impact factor: 17.425

5.  Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages.

Authors:  N Ouchi; S Kihara; Y Arita; M Nishida; A Matsuyama; Y Okamoto; M Ishigami; H Kuriyama; K Kishida; H Nishizawa; K Hotta; M Muraguchi; Y Ohmoto; S Yamashita; T Funahashi; Y Matsuzawa
Journal:  Circulation       Date:  2001-02-27       Impact factor: 29.690

6.  Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages.

Authors:  T Yokota; K Oritani; I Takahashi; J Ishikawa; A Matsuyama; N Ouchi; S Kihara; T Funahashi; A J Tenner; Y Tomiyama; Y Matsuzawa
Journal:  Blood       Date:  2000-09-01       Impact factor: 22.113

Review 7.  ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism.

Authors:  Anders H Berg; Terry P Combs; Philipp E Scherer
Journal:  Trends Endocrinol Metab       Date:  2002-03       Impact factor: 12.015

8.  Circulating adiponectin levels are reduced in nonobese but insulin-resistant first-degree relatives of type 2 diabetic patients.

Authors:  F Pellmé; U Smith; T Funahashi; Y Matsuzawa; H Brekke; O Wiklund; M-R Taskinen; P-A Jansson
Journal:  Diabetes       Date:  2003-05       Impact factor: 9.461

9.  Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism.

Authors:  Otto Tschritter; Andreas Fritsche; Claus Thamer; Michael Haap; Fatemeh Shirkavand; Stefanie Rahe; Harald Staiger; Elke Maerker; Hans Häring; Michael Stumvoll
Journal:  Diabetes       Date:  2003-02       Impact factor: 9.461

10.  Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice.

Authors:  J Fruebis; T S Tsao; S Javorschi; D Ebbets-Reed; M R Erickson; F T Yen; B E Bihain; H F Lodish
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-06       Impact factor: 11.205

View more
  103 in total

1.  Portal vein and systemic adiponectin concentrations are closely linked with hepatic glucose and lipoprotein kinetics in extremely obese subjects.

Authors:  Faidon Magkos; Elisa Fabbrini; Bruce W Patterson; J Christopher Eagon; Samuel Klein
Journal:  Metabolism       Date:  2011-05-31       Impact factor: 8.694

Review 2.  Inflammation and fibrogenesis in steatohepatitis.

Authors:  Hideki Fujii; Norifumi Kawada
Journal:  J Gastroenterol       Date:  2012-02-07       Impact factor: 7.527

3.  Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice.

Authors:  Xiaokun Ding; Neeraj K Saxena; Songbai Lin; Nitika Arora Gupta; Narita Gupta; Frank A Anania
Journal:  Hepatology       Date:  2006-01       Impact factor: 17.425

Review 4.  Clinical review of nonalcoholic steatohepatitis in liver surgery and transplantation.

Authors:  Amit D Tevar; Calissia Clarke; Jiang Wang; Steven M Rudich; E Steve Woodle; Alex B Lentsch; Michael L Edwards
Journal:  J Am Coll Surg       Date:  2010-04       Impact factor: 6.113

5.  Low serum adiponectin is a predictor of progressing to nonalcoholic fatty liver disease.

Authors:  Hongmei Zhang; Yixin Niu; Hongxia Gu; Shuai Lu; Weiwei Zhang; Xiaoyong Li; Zhen Yang; Li Qin; Qing Su
Journal:  J Clin Lab Anal       Date:  2018-11-02       Impact factor: 2.352

Review 6.  Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.

Authors:  Sanja Stojsavljević; Marija Gomerčić Palčić; Lucija Virović Jukić; Lea Smirčić Duvnjak; Marko Duvnjak
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

Review 7.  Adiponectin as a Potential Therapeutic Target for Prostate Cancer.

Authors:  Hanuma Kumar Karnati; Manas Kumar Panigrahi; Yazhou Li; David Tweedie; Nigel H Greig
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

Review 8.  Kupffer cells in non-alcoholic fatty liver disease: the emerging view.

Authors:  György Baffy
Journal:  J Hepatol       Date:  2009-03-31       Impact factor: 25.083

9.  Effect of CAR activation on selected metabolic pathways in normal and hyperlipidemic mouse livers.

Authors:  Tadeja Rezen; Viola Tamasi; Anita Lövgren-Sandblom; Ingemar Björkhem; Urs A Meyer; Damjana Rozman
Journal:  BMC Genomics       Date:  2009-08-19       Impact factor: 3.969

Review 10.  Pathogenesis of non-alcoholic fatty liver disease.

Authors:  J K Dowman; J W Tomlinson; P N Newsome
Journal:  QJM       Date:  2009-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.